Seng Chin Mah, PhD, is Chief Executive Officer of the Canyon Pharmaceuticals group. He has over 25 years of experience in the Pharma industry. Prior to joining Canyon Pharmaceuticals, Dr. Mah was recently Head of Development of the Integration Office during the integration of Chiron into Novartis, and has previously held positions including the Global Head of Clinical Safety & Epidemiology, Head of Drug Regulatory Affairs Europe. He also had oversight responsibility for Clinical Quality Assurance. Dr. Mah was also a member of the board for Novartis Europharm Ltd. During his tenure with Novartis and Ciba, Dr. Mah has driven transformational programs, managed large global organizations, and achieved significant business results such as the global registration of major products including Diovan. Dr. Mah has worked extensively on both development projects and marketed products. He has held numerous research and academia positions, and is currently on the boards of several biotech companies.
MARINA VON SCHÖNAU
Marina von Schönau is currently active with companies in the private equity space. She focuses on advising venture opportunities, growth scenarios and restructuring. Previously, she has worked in senior positions at different multi-national companies in the pharmaceutical sector including Jansen Cilag AG and Bayer (Schweiz) AG where she gained in depth knowledge of marketing, product launches and leadership. She was also a member of an international marketing frame group for a new product and drove e-business ideas. Marina von Schönauholds a Master’s degree in Food Science from ETH Zurich.
DANIEL O.A. RÜEDI
Daniel Rüedi is one of the partners of the private bank Baumann & Cie, Basel. He is a certified financial analyst and fund manager. Moreover, he holds an MBA from Rochester-Bern. Daniel Rüedi started his career at Bank Sarasin, thereafter changing to the Private Banking division of the Swiss Banking Corporation before coming back in 1989 to Bank Sarasin as Head Portfolio Manager for institutional clients. In 1997, he became head of Portfolio Management Equities at Novartis International. Before joining Baumann & Cie in 2005, Daniel Rüedi was in charge of the Portfolio Management at Clariden Bank, Basel. In 2008, he became partner at Baumann & Cie.
Board Member & CEO
Marc completed his studies in Biology at the University of Freiburg (Germany) and the University of Queensland (Australia). He holds a PhD in Biotechnology from the ETH Zurich. Besides his excellent skills in molecular biology, he gained business experience as Associate Intern at McKinsey & Company and insights to intellectual property rights at the patent offices Ernest T. Freylinger SA (Luxemburg) and Joachim Stuercken GmbH (Germany). Marc is winner of the Venture Leaders 2008 award.
David Hundstad, MD, is Associate Professor of Pediatrics and Molecular Microbiology at Washington University School of Medicine, St. Louis, Missouri, USA. He is a board-certified pediatrician and infectious diseases specialist and directs an NIH-funded basic research program in bacterial pathogenesis. His primary research focus is Gram-negative urinary tract infection (E. coli and Klebsiella), including pathogen manipulation of host immune responses and development of novel nanotherapeutics for persistent bladder infection. The laboratory also features projects in the areas of bacterial pneumonia and MRSA infections. He has thus far authored nearly 50 scientific and medical publications.